Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Sykora, Karl-Walter  [Clear All Filters]
2015
Boztug H, Sykora K-W, Slatter M, Zecca M, Veys P, Lankester A, Cant A, Skinner R, Wachowiak J, Glogova E, et al. European society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2015.
Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015.
Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, et al. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents. Blood. 2015.
2019
Schultze-Florey RE, Tischer-Zimmermann S, Heuft H-G, Priesner C, Lamottke B, Heim A, Sauer M, Sykora K-W, Blasczyk R, Eiz-Vesper B, et al. Transfer of Hexon and Penton selected adenovirus-specific T cells for refractory adenovirus infection after haploidentical stem cell transplantation. Transpl Infect Dis. 2019:e13201.
2023
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.
Li X, Kalwak K, Beier R, Kehne J, Möller A-K, Baumgart J, Beelen DW, Hilger RA, Vora A, Sykora K-W. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. Drug Metab Pharmacokinet. 2023;52:100515.
Sykora K-W, Beier R, Schulz A, Cesaro S, Greil J, Goździk J, Sedlacek P, Bader P, Schulte J, Zecca M, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2023.